What topics does this cannabis study cover?

This study covers research on: THC.

Where was this research published?

Published in Pharmacological research on February 16, 2026.

THC

How a Single Cannabis Dose Can Trigger Drug Tests Weeks Later

Q: What did this Review find?

**Low doses of THC (1.0-5.0 mg) can exceed workplace testing thresholds**, especially with oral consumption

Urinary Δ9-tetrahydrocannabinol and metabolite concentrations following cannabis use: A systematic review.

Pharmacological research • February 16, 2026 • Review • Moderately Relevant

🤖

AI Summary

This systematic review provides crucial insights into tetrahydrocannabinol (THC) detection in urine tests, addressing a critical concern for cannabis users across various contexts. Researchers analyzed 92 studies to understand how different patterns of cannabis consumption affect urine THC metabolite concentrations, with a focus on workplace and sports testing thresholds.

The study revealed surprising sensitivity in current testing methods, demonstrating that even low doses of THC can trigger positive test results. Low single doses as small as 1.0-5.0 mg could potentially exceed standard workplace testing thresholds, particularly when cannabis is consumed orally. For frequent users, metabolites can remain detectable for weeks after cessation, creating significant challenges for individuals subject to drug testing in professional or competitive environments.

Key implications extend beyond simple detection, highlighting the complex interactions between cannabis consumption, metabolism, and testing protocols. The research suggests that current testing thresholds may not accurately reflect recent use or impairment, potentially leading to unintended consequences for individuals in workplace, athletic, or legal settings. This comprehensive review provides valuable context for understanding the nuanced relationship between THC consumption and detection methods.

💡 Key Findings

Low doses of THC (1.0-5.0 mg) can exceed workplace testing thresholds, especially with oral consumption

High

85%

Weekly to daily cannabis users may test positive for weeks after stopping use

High

90%

Standard workplace threshold (15ng/mL) and WADA limit (180ng/mL) can be triggered by minimal cannabis consumption

High

80%

📄 Original Abstract

Urine testing is used in a variety of contexts to identify cannabis use. Most tests target 11-nor-9-carboxy-Δ⁹-tetrahydrocannabinol (11-COOH-THC), the terminal metabolite of Δ⁹-tetrahydrocannabinol (THC), the principal intoxicant in cannabis. Different authorities use different threshold concentrations to define a positive test. This systematic review synthesised the urinary THC and THC-metabolite concentrations reported in prior studies involving administration of cannabis/cannabis-based products (acute and repeated dosing) and users of such products (during use and extended abstinence). The overall objectives were to: (1) clarify how different use patterns affect these concentrations; and (2) contextualise the thresholds applied in key contexts - specifically, workplaces (and workplace-aligned contexts, e.g., criminal justice) and competitive sport. Ninety-two eligible studies were identified and included. Standard workplace threshold (15ng/mL total 11-COOH-THC): Low single doses (i.e., 1.0-5.0mg) and very low repeated doses (i.e., <1.0mg/day) of THC were sometimes sufficient to exceed the workplace threshold, particularly with oral ingestion. Weekly to daily cannabis users could remain above this threshold for weeks following cessation. World Anti-Doping Agency (WADA) Decision Limit (180ng/mL total 11-COOH-THC): Low-to-moderate oral doses (i.e., 10mg) and moderate inhaled doses (i.e., 15-20mg) of THC were sometimes sufficient to exceed the WADA Decision Limit, as was weekly cannabis use. Weekly to daily cannabis users often fell below this threshold within a week of cessation, although heavy users took longer. This synthesis may assist policymakers in selecting appropriate urine-testing thresholds and in educating individuals about the risks of testing positive following different patterns of cannabis use.

Paper Type

📚 Review

Publication

Journal: Pharmacological research
Published: February 16, 2026
PMID: 41707818
DOI: 10.1016/j.phrs.2026.108142

Authors (6)

Danielle McCartney Sydney Pharmacy School, The University of Sydney, NSW, Australia. Electronic address: danielle.mccartney@sydney.edu.au.
Christopher Irwin School of Allied Health, Sport and Social Work, Griffith University, QLD, Australia.
Jonathon C Arnold Sydney Pharmacy School, The University of Sydney, NSW, Australia; Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney, NSW, Australia; Brain and Mind Centre, The University of Sydney, NSW, Australia.
Rebecca Gordon Sydney Pharmacy School, The University of Sydney, NSW, Australia; Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney, NSW, Australia; Brain and Mind Centre, The University of Sydney, NSW, Australia.
Andrew J McLachlan Sydney Pharmacy School, The University of Sydney, NSW, Australia.
+1 more authors